SavedAdd your journal

Journals / Güncel Retina Dergisi / 2019 / Cilt: 3 - Sayı: 2

Non-Routine Therapies for the Treatment of Branched Retinal Vein Occlusion and Macular Edema

Retinal Ven Dal Tıkanıklığı ve Maküla Ödemi Tedavisinde Rutin Dışı Tedaviler

Mustafa ATAŞ
Pages
120–128
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review the treatment modalities other than routinely performed anti-VEGF, steroid and laser therapy in macular edema secondary to branch retinal vein occlusion and emerging therapies will be overviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy and is considered to be an important cause of visual loss.
📊
Key Findings & Data:There are several treatment modalities for branch retinal vein occlusion and specifically for its complications, such as macular edema, vitreous hemorrhage, retinal neovascularization, and retinal detachment.
💡
Conclusion & Impact:In this review the treatment modalities other than routinely performed anti-VEGF, steroid and laser therapy in macular edema secondary to branch retinal vein occlusion and emerging therapies will be overviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy and is considered to be an important cause of visual loss. There are several treatment modalities for branch retinal vein occlusion and specifically for its complications, such as macular edema, vitreous hemorrhage, retinal neovascularization, and retinal detachment. These treatment modalities are anti-aggregative therapy and fibrinolysis, isovolemic hemodilution, vitrectomy with or without sheathotomy, peripheral scatter and macular grid retinal laser therapy, non-steroid agents, intravitreal steroids ( triamcinolone, and dexamethasone implants), and intravitreal anti-vascular endothelial growth factors (anti-VEGFs) (bevacizumab, ranibizumab, aflibercept). In this review the treatment modalities other than routinely performed anti-VEGF, steroid and laser therapy in macular edema secondary to branch retinal vein occlusion and emerging therapies will be overviewed.

Özet

Retina ven tıkanıklıkları (RVT) diyabetik retinopatiden sonra ikinci sıklıkta görülen retinanın vasküler hastalıklarıdır ve ciddi görme kaybına sebep olabilirler. Retina ven dal tıkanıklıkları komplikasyonlarından vitreus hemorajisi, retinal neovaskülarizasyon, retina dekolmanı ve özellikle maküler ödem için birçok tedavi yaklaşımı vardır. Bu tedavi yaklaşımları, anti-agregan tedavi ve fibrinolizis, izovolemik hemodilüsyon, vitrektomi tek başına ya da vitrektomi ile birlikte şitotomi, periferal skater ve maküler grid lazer tedavisi, non-streoid ajanlar, intravitreal steroidler (triamsinolon ve deksametazon implant) ve intravitreal antivasküler endotelyal büyüme faktörleri (anti-VEGF) (bevacizumab, ranibizumab, aflibercept) içerir. Bu derlemede retinal ven dal tıkanıklığı ve maküla ödemi tedavisinde rutinde kullanılan anti-VEGF, steroid ve lazer dışındaki tedaviler ve yeni uygulamalar gözden geçirilecektir

🔖

Cite This Article

ATAŞ, M. (2019). Non-Routine Therapies for the Treatment of Branched Retinal Vein Occlusion and Macular Edema. Güncel Retina Dergisi, Cilt: 3 - Sayı: 2, 120–128. https://ajindex.com/articles/204981

References (15)

  1. 1 Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000
  2. 133– 141. 2. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008
  3. 33(2):111–131.] 3. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 1986
  4. 104(1):34–41. 4. Bessette A, PK. Branch Retinal Vein Occlusion. Ryan’s Retina, Sixth Edition. Published January 1, 2018. Chapter 56, P
  5. ClinicalKey. Erişim tarihi 03.02.2018. 5. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994
  6. 117(4):429–441. 6. Parodi MB, Bandello F. Branch retinal vein occlusion: Classification and treatment. Ophthalmologica 2009
  7. 223(5):298–305. 7. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et. al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010
  8. 117(2):313-319. 8.Ehlers JP, Kim SJ, Yeh S, Thorne JE, Mruthyunjaya P, Schoenberger SD, et. al. Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017
  9. 124(9):1412-23. 9. Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease CaseControl Study Group. Ophthalmology. 1993
  10. 100(3):423-428. 10 Joffe L, Goldberg RE, Magargal LE, Annesley WH. Macular branch vein occlusion. Ophthalmology. 1980:87(2)
  11. The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J O phthalmol. 1993
  12. 116(3):286-96. 12. Johnston RL, Brucker AJ, Steinmann W, Hoffman ME, Holmes JH. Risk factors of branch retinal vein occlusion. Arch Ophthalmol 1985
  13. 103(12):1831- 2. 13. Rabinowicz IM, Litman S, Michaelson IC. Branch venous thrombosis--a pathological report. Trans Ophthalmol Soc U K. 1969
  14. Acar N. Retina Ven-Dal Tıkanıklığı ve Hemisferik Tıkanma. Turkiye Klinikleri J Ophthalmol-Special Topics. 2011
  15. 4(3):40-50 15.Janssen MCH, den Heijer M, Cruysberg JRM, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complicatioof atherosclerosis?